impact factor, citescore

Psoriatic arthritis (PsA)


Can biologic therapies be withdrawn or tapered in psoriatic arthritis?

, ,


2013 Vol.31, N°4 ,Suppl.78
PI 0051, PF 0053
Psoriatic arthritis (PsA)

Free to view
(click on article PDF icon to read the article)

PMID: 24129138 [PubMed]

Received: 26/08/2013
Accepted : 26/08/2013
In Press: 04/10/2013
Published: 04/10/2013


There is a paucity of data on tapering and withdrawing therapy in psoriatic arthritis but advances in treatment and outcome measures suggest it is now time to be looking more closely at this. Several highly effective therapies are available providing the opportunity to achieve low disease activity. However, these therapies are associated with a marked increase in direct costs and patients are exposed to potentially life threatening adverse events. In addition to effective therapies the science of outcome assessment means that there are now suitable validated criteria for low disease activity which will allow both treat-to-target and a suitable measure of continuing low disease. Given these conditions, suitably designed randomized controlled trials of treatment withdrawal are now needed. Such studies will allow us to determine disease characteristics predictive of flare upon treatment withdrawal. In this way identifying which patients can successfully stop therapy will allow a more personalized approach to treatment decisions in PsA and will minimise risks and costs associated with ongoing therapy.

Rheumatology Article